News Headlines

  1. Arcturus Therapeutics Announces Completion Of Merger With Alcobra Ltd. And Commences Trading On The Nasdaq Global Market
    11/16/2017

    Arcturus Therapeutics Ltd. (Nasdaq:ARCT), a leading RNA medicines company, announced today the completion of its previously announced merger with Alcobra Ltd. (Nasdaq:ADHD), effective as of November 15, 2017.

  2. Poor Aggregation Will See ADC Targets Fail Or Face Long Delays
    11/14/2017

    ADC Biotechnology (ADC Bio)‘s leading experts warn that best in class ADCs are being overlooked due to critical aggregation control problems.

  3. Quotient Sciences Acquires Pharmaterials, A UK-Based Contract Development And Manufacturing Organization
    11/14/2017

    Quotient Sciences (“Quotient”), the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K.

  4. FDA Approves Pill With Sensor That Digitally Tracks If Patients Have Ingested Their Medication
    11/13/2017

    The U.S. Food and Drug Administration recently approved the first drug in the U.S. with a digital ingestion tracking system.

  5. Quotient Sciences Launches As The New Global Identity For Quotient Clinical
    11/10/2017

    Quotient Clinical, the drug development services organization, announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research.

  6. Aquila BioMedical Secures Macrophage Pharma Agreement
    11/9/2017

    Aquila BioMedical Ltd., an innovative preclinical contract research organisation (CRO) now part of Concept Life Sciences group, has secured an extended agreement with UK-based biotech firm Macrophage Pharma Ltd. to support its preclinical immuno-oncology programmes.

  7. Vetter Expands Its Footprint In Asia Pacific Region
    11/9/2017

    Vetter, one of the global leaders in prefilled drug delivery systems, recently announced the official opening of a new branch office in South Korea.

  8. Sangamo Announces Strategic Investment In Manufacturing And Appointment Of Andy Ramelmeier As Head Of Technical Operations
    11/9/2017

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced a strategic investment in manufacturing, including an expanded commitment with Brammer Bio, plans to build a proprietary cGMP manufacturing facility in the new Sangamo corporate headquarters in Brisbane, California, as well as the appointment of Andy Ramelmeier, PhD, as Senior Vice President, Head of Technical Operations and Manufacturing.

  9. Alcami Announces Manufacturing Agreement For Solasia’s Active Pharmaceutical Ingredient Darinaparsin
    11/9/2017

    Alcami, a leading provider of custom end-to-end development and manufacturing services for the pharmaceutical and biotechnology industries, recently announces it has finalized manufacturing and quality agreements with Solasia Pharma, K.K. for the clinical supply manufacture of the active pharmaceutical ingredient (API) darinaparsin, a novel mitochondrial-targeted agent developed for the treatment of various hematologic and solid cancers. By Catherine Hanley

  10. Cambrex Invests In New Small Scale Capacity At Its Charles City, Iowa Facility
    11/8/2017

    Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), recently announced that it has completed an expansion of cGMP small scale capacity at its Charles City, Iowa plant.